Cypress Wealth Services LLC Has $1.54 Million Holdings in Becton Dickinson and Co (BDX)

Cypress Wealth Services LLC boosted its stake in Becton Dickinson and Co (NYSE:BDX) by 16.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,184 shares of the medical instruments supplier’s stock after purchasing an additional 893 shares during the quarter. Cypress Wealth Services LLC’s holdings in Becton Dickinson and were worth $1,544,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. IMS Capital Management bought a new stake in shares of Becton Dickinson and during the 3rd quarter valued at about $29,000. Oregon Public Employees Retirement Fund boosted its position in shares of Becton Dickinson and by 22,485.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 6,545,502 shares during the last quarter. RPG Investment Advisory LLC bought a new stake in shares of Becton Dickinson and during the 1st quarter valued at about $32,000. Nalls Sherbakoff Group LLC bought a new stake in shares of Becton Dickinson and during the 4th quarter valued at about $34,000. Finally, Aspire Private Capital LLC bought a new stake in shares of Becton Dickinson and during the 4th quarter valued at about $39,000. Institutional investors and hedge funds own 84.87% of the company’s stock.

Shares of NYSE BDX opened at $227.89 on Friday. The stock has a market cap of $61.32 billion, a P/E ratio of 20.70, a PEG ratio of 1.74 and a beta of 1.21. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.97. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.58 by $0.12. The company had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. Becton Dickinson and’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same period last year, the firm posted $2.48 EPS. As a group, equities analysts expect that Becton Dickinson and Co will post 12.08 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 8th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.35%. Becton Dickinson and’s dividend payout ratio is 27.97%.

A number of analysts have recently issued reports on the company. Zacks Investment Research downgraded Becton Dickinson and from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Barclays lifted their price target on Becton Dickinson and from $260.00 to $266.00 and gave the company an “equal weight” rating in a research report on Monday, April 15th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Raymond James dropped their price target on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a research report on Tuesday, March 19th. Finally, TheStreet raised Becton Dickinson and from a “c+” rating to an “a” rating in a report on Tuesday, February 5th. One research analyst has rated the stock with a sell rating, five have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Becton Dickinson and presently has a consensus rating of “Buy” and a consensus price target of $256.25.

In related news, CEO Vincent A. Forlenza sold 11,340 shares of the firm’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $250.40, for a total transaction of $2,839,536.00. Following the transaction, the chief executive officer now directly owns 227,250 shares of the company’s stock, valued at approximately $56,903,400. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Vincent A. Forlenza sold 8,309 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $255.13, for a total value of $2,119,875.17. Following the transaction, the chief executive officer now directly owns 222,785 shares in the company, valued at $56,839,137.05. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,684 shares of company stock worth $7,518,574. 0.12% of the stock is currently owned by insiders.

WARNING: “Cypress Wealth Services LLC Has $1.54 Million Holdings in Becton Dickinson and Co (BDX)” was published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/cypress-wealth-services-llc-has-1-54-million-holdings-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: Certificate of Deposit (CD) For Risk Adverse Investors?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.